Paul Zabierek
Cognoa CEO Brent Vaughan to Speak at HLTH and CNS Summit.
Paul Zabierek October 28, 2019
READ MORE » Cognoa Launches Pivotal Study of the First Digital Diagnostic for Autism.
Paul Zabierek October 24, 2019
READ MORE » 
What are the challenges and opportunities of running clinical trials of digital therapeutics?
Paul Zabierek September 26, 2019
READ MORE » Cognoa and EVERSANA™ announce partnership to advance the commercialization standard for prescription digital medicines.
Paul Zabierek September 10, 2019
READ MORE » When Are We Sure? Predictors of Clinician Certainty in the Diagnosis of Autism Spectrum Disorder.
Paul Zabierek April 1, 2019
READ MORE » Cognoa Receives FDA Breakthrough Designations for Autism Diagnostic and Digital Therapeutic Devices.
Paul Zabierek February 6, 2019
READ MORE » Paul Zabierek
Cognoa CEO Brent Vaughan to Speak at HLTH and CNS Summit.
Paul Zabierek October 28, 2019
READ MORE » Cognoa Launches Pivotal Study of the First Digital Diagnostic for Autism.
Paul Zabierek October 24, 2019
READ MORE » What are the challenges and opportunities of running clinical trials of digital therapeutics?
Paul Zabierek September 26, 2019
READ MORE » Cognoa and EVERSANA™ announce partnership to advance the commercialization standard for prescription digital medicines.
Paul Zabierek September 10, 2019
READ MORE » When Are We Sure? Predictors of Clinician Certainty in the Diagnosis of Autism Spectrum Disorder.
Paul Zabierek April 1, 2019
READ MORE » Cognoa Receives FDA Breakthrough Designations for Autism Diagnostic and Digital Therapeutic Devices.
Paul Zabierek February 6, 2019
READ MORE »